Open in app

A booster dose of Covaxin improves vaccination efficacy against Delta and Omicron variants: ICMR Study

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:
(Image Courtesy: - Medical Dialogue)

In a Syrian hamster model, the protective effectiveness of Bharat Biotech's Covaxin after two and three dosage immunisations against the Delta variation, as well as the efficacy of the Covaxin against Omicron variants, were investigated (animal model to study human-associated diseases). After virus challenge, the antibody response, clinical observations, viral load decrease, and lung disease severity were all observed. The study's findings were released on bioRxiv, a pre-print platform, on June 14 and have not been peer reviewed. We could see the benefit of the booster dose immunisation in the Delta infection research, where we examined the protective response between the two and three-dose regimens. Despite the fact that neutralising antibody levels were equal between the groups, the severity of lung illness was observed to be decreased more following the three-dose vaccination.In both the two-dose and three-dose immunised animals, virus shedding and viral organ load were significantly decreased, showing vaccination effectiveness against the Delta variant. In the second research, the protective response against Omicron variants BA.1 and BA.2 was examined following three-dose vaccinations. The immunised groups had lower virus shedding, lung viral load, and lung disease severity than the placebo groups. Covaxin booster vaccination broadens the protective immune response and decreases illness severity against the Delta and Omicron variant infections, according to the findings of this study.

Reference: -